1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Zura Bio Limited

Zura Bio Limited

94E.F
Zura Bio Limitedundefined flagFrankfurt Stock Exchange
4.50
EUR
+0.02
- -
292.60MMarket Cap
Zura Bio Limited
94E.F
(Frankfurt Stock Exchange)

Recent

price

4.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
-12.19
-1.83
-0.7
-0.73
-0.75
Basic EPS, GAAP
- -
- -
-6.25
-0.7
-0.44
-0.69
-0.72
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-15.19
-3.13
-2.08
-2.38
-2.48
Book Value per Share
- -
- -
-10.45
2.41
2.13
1.08
2.16
Tangible Book Value per Share
- -
- -
2
33
75
94
100
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-26
-60
-52
-69
-75
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
5
-13
81
159
100
215
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
130
-8
-22
80
160
102
217
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
74
95
Market Capitalization
287
501
575

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
142
112
227
Cash, Cash Equivalents & STI
139
109
226
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
25
12
12
Payables & Accruals
18
9
11
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-64%
-36.55%
Free Cash Flow
- -
- -
95.86%
Net Income, GAAP
- -
- -
31%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.18
-0.14
-0.24
- -
-0.7
2025
-0.19
-0.17
-0.19
- -
-0.73
2026
-0.22
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Telix Pharmaceuticals Limited (TLX.AX)
Taiwan Liposome Company, Ltd. (TLC)
EZZ Life Science Holdings Limited (EZZ.AX)
Asarina Pharma AB (publ) (ASAP.ST)
Altamira Therapeutics Ltd. (CYTO)
Pharmicell Co., Ltd. (005690.KS)
Business
Zura Bio Limited operates as a clinical-stage biotechnology firm, dedicated to advancing innovative therapeutic antibodies for a spectrum of immune and inflammatory disorders. Its lead pipeline asset, tibulizumab (ZB-106), a bispecific dual antagonist targeting both IL-17A and BAFF, is presently undergoing two distinct Phase 2 clinical trials for systemic sclerosis and hidradenitis suppurativa. The company is also progressing crebankitug (ZB-168), an anti-IL7R alpha inhibitor designed to modulate diseases influenced by IL-7 and TSLP pathways, and torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to mitigate inflammation. Both ZB-168 and ZB-880 have successfully completed Phase 1/1b studies and are being prepared for further Phase 2 development. The company's headquarters are located in Henderson, Nevada.